Multicenter Study

. 2018 Mar;45(3):378-384.

doi: 10.3899/jrheum.170379. Epub 2018 Feb 1.

Gaps in Diagnosis and Treatment of Cardiovascular Risk Factors in Patients with Psoriatic Disease: An International Multicenter Study

Lihi Eder^{1

2}, Paula Harvey^{3

4}, Vinod Chandran^{3

4}, Cheryl F Rosen^{3

4}, Jan Dutz^{3

4}, James T Elder^{3

4}, Proton Rahman^{3

4}, Christopher T Ritchlin^{3

4}, Sherry Rohekar^{3

4}, Richard Hayday^{3

4}, Snezana Barac^{3

4}, Joy Feld^{3

4}, Devy Zisman^{3

4}, Dafna D Gladman^{3

4}

Affiliations

¹ From the Women's College Research Institute, Women's College Hospital; Department of Medicine, University of Toronto; Centre for Prognosis Studies in the Rheumatic Diseases, Toronto Western Hospital; Division of Dermatology, University of Toronto, Toronto Western Hospital, Toronto; Western University, London, Ontario; University of British Columbia, Vancouver, British Columbia; Memorial University of Newfoundland, St. John's, Newfoundland; University of Manitoba; Winnipeg Clinic, Winnipeg, Manitoba, Canada; University of Michigan Medical School, Ann Arbor, Michigan; Allergy, Immunology and Rheumatology Division, University of Rochester Medical Center, Rochester, New York, USA; Rheumatology Unit, Carmel Medical Center, Haifa, Israel. lihi.eder@wchospital.ca.
² L. Eder, MD, PhD, Women's College Research Institute, Women's College Hospital, and Department of Medicine, University of Toronto; P. Harvey, BMBS, PhD, Women's College Research Institute, Women's College Hospital, and Department of Medicine, University of Toronto; V. Chandran, MD, DM, PhD, Department of Medicine, University of Toronto, and Centre for Prognosis Studies in the Rheumatic Diseases, Toronto Western Hospital; C.F. Rosen, MD, FRCPC, Department of Medicine, University of Toronto, and Division of Dermatology, University of Toronto, Toronto Western Hospital; J. Dutz, MD, FRCPC, University of British Columbia; J.T. Elder, MD, PhD, University of Michigan Medical School; P. Rahman, MD, MSc, FRCPC, Memorial University of Newfoundland; C.T. Ritchlin, MD, MPH, Allergy, Immunology and Rheumatology Division, University of Rochester Medical Center; S. Rohekar, MD, FRCPC, Western University; R. Hayday, MD, FRCPC, University of Manitoba; S. Barac, MD, FRCPC, Winnipeg Clinic; J. Feld, MD, Rheumatology Unit, Carmel Medical Center; D. Zisman, MD, Rheumatology Unit, Carmel Medical Center; D.D. Gladman, MD, FRCPC, Department of Medicine, University of Toronto, and Centre for Prognosis Studies in the Rheumatic Diseases, Toronto Western Hospital. lihi.eder@wchospital.ca.
³ From the Women's College Research Institute, Women's College Hospital; Department of Medicine, University of Toronto; Centre for Prognosis Studies in the Rheumatic Diseases, Toronto Western Hospital; Division of Dermatology, University of Toronto, Toronto Western Hospital, Toronto; Western University, London, Ontario; University of British Columbia, Vancouver, British Columbia; Memorial University of Newfoundland, St. John's, Newfoundland; University of Manitoba; Winnipeg Clinic, Winnipeg, Manitoba, Canada; University of Michigan Medical School, Ann Arbor, Michigan; Allergy, Immunology and Rheumatology Division, University of Rochester Medical Center, Rochester, New York, USA; Rheumatology Unit, Carmel Medical Center, Haifa, Israel.
⁴ L. Eder, MD, PhD, Women's College Research Institute, Women's College Hospital, and Department of Medicine, University of Toronto; P. Harvey, BMBS, PhD, Women's College Research Institute, Women's College Hospital, and Department of Medicine, University of Toronto; V. Chandran, MD, DM, PhD, Department of Medicine, University of Toronto, and Centre for Prognosis Studies in the Rheumatic Diseases, Toronto Western Hospital; C.F. Rosen, MD, FRCPC, Department of Medicine, University of Toronto, and Division of Dermatology, University of Toronto, Toronto Western Hospital; J. Dutz, MD, FRCPC, University of British Columbia; J.T. Elder, MD, PhD, University of Michigan Medical School; P. Rahman, MD, MSc, FRCPC, Memorial University of Newfoundland; C.T. Ritchlin, MD, MPH, Allergy, Immunology and Rheumatology Division, University of Rochester Medical Center; S. Rohekar, MD, FRCPC, Western University; R. Hayday, MD, FRCPC, University of Manitoba; S. Barac, MD, FRCPC, Winnipeg Clinic; J. Feld, MD, Rheumatology Unit, Carmel Medical Center; D. Zisman, MD, Rheumatology Unit, Carmel Medical Center; D.D. Gladman, MD, FRCPC, Department of Medicine, University of Toronto, and Centre for Prognosis Studies in the Rheumatic Diseases, Toronto Western Hospital.

PMID: 29419462
PMCID: PMC5845845
DOI: 10.3899/jrheum.170379

Multicenter Study

Gaps in Diagnosis and Treatment of Cardiovascular Risk Factors in Patients with Psoriatic Disease: An International Multicenter Study

Lihi Eder et al. J Rheumatol. 2018 Mar.

. 2018 Mar;45(3):378-384.

doi: 10.3899/jrheum.170379. Epub 2018 Feb 1.

Authors

Affiliations

¹ From the Women's College Research Institute, Women's College Hospital; Department of Medicine, University of Toronto; Centre for Prognosis Studies in the Rheumatic Diseases, Toronto Western Hospital; Division of Dermatology, University of Toronto, Toronto Western Hospital, Toronto; Western University, London, Ontario; University of British Columbia, Vancouver, British Columbia; Memorial University of Newfoundland, St. John's, Newfoundland; University of Manitoba; Winnipeg Clinic, Winnipeg, Manitoba, Canada; University of Michigan Medical School, Ann Arbor, Michigan; Allergy, Immunology and Rheumatology Division, University of Rochester Medical Center, Rochester, New York, USA; Rheumatology Unit, Carmel Medical Center, Haifa, Israel. lihi.eder@wchospital.ca.
² L. Eder, MD, PhD, Women's College Research Institute, Women's College Hospital, and Department of Medicine, University of Toronto; P. Harvey, BMBS, PhD, Women's College Research Institute, Women's College Hospital, and Department of Medicine, University of Toronto; V. Chandran, MD, DM, PhD, Department of Medicine, University of Toronto, and Centre for Prognosis Studies in the Rheumatic Diseases, Toronto Western Hospital; C.F. Rosen, MD, FRCPC, Department of Medicine, University of Toronto, and Division of Dermatology, University of Toronto, Toronto Western Hospital; J. Dutz, MD, FRCPC, University of British Columbia; J.T. Elder, MD, PhD, University of Michigan Medical School; P. Rahman, MD, MSc, FRCPC, Memorial University of Newfoundland; C.T. Ritchlin, MD, MPH, Allergy, Immunology and Rheumatology Division, University of Rochester Medical Center; S. Rohekar, MD, FRCPC, Western University; R. Hayday, MD, FRCPC, University of Manitoba; S. Barac, MD, FRCPC, Winnipeg Clinic; J. Feld, MD, Rheumatology Unit, Carmel Medical Center; D. Zisman, MD, Rheumatology Unit, Carmel Medical Center; D.D. Gladman, MD, FRCPC, Department of Medicine, University of Toronto, and Centre for Prognosis Studies in the Rheumatic Diseases, Toronto Western Hospital. lihi.eder@wchospital.ca.
³ From the Women's College Research Institute, Women's College Hospital; Department of Medicine, University of Toronto; Centre for Prognosis Studies in the Rheumatic Diseases, Toronto Western Hospital; Division of Dermatology, University of Toronto, Toronto Western Hospital, Toronto; Western University, London, Ontario; University of British Columbia, Vancouver, British Columbia; Memorial University of Newfoundland, St. John's, Newfoundland; University of Manitoba; Winnipeg Clinic, Winnipeg, Manitoba, Canada; University of Michigan Medical School, Ann Arbor, Michigan; Allergy, Immunology and Rheumatology Division, University of Rochester Medical Center, Rochester, New York, USA; Rheumatology Unit, Carmel Medical Center, Haifa, Israel.
⁴ L. Eder, MD, PhD, Women's College Research Institute, Women's College Hospital, and Department of Medicine, University of Toronto; P. Harvey, BMBS, PhD, Women's College Research Institute, Women's College Hospital, and Department of Medicine, University of Toronto; V. Chandran, MD, DM, PhD, Department of Medicine, University of Toronto, and Centre for Prognosis Studies in the Rheumatic Diseases, Toronto Western Hospital; C.F. Rosen, MD, FRCPC, Department of Medicine, University of Toronto, and Division of Dermatology, University of Toronto, Toronto Western Hospital; J. Dutz, MD, FRCPC, University of British Columbia; J.T. Elder, MD, PhD, University of Michigan Medical School; P. Rahman, MD, MSc, FRCPC, Memorial University of Newfoundland; C.T. Ritchlin, MD, MPH, Allergy, Immunology and Rheumatology Division, University of Rochester Medical Center; S. Rohekar, MD, FRCPC, Western University; R. Hayday, MD, FRCPC, University of Manitoba; S. Barac, MD, FRCPC, Winnipeg Clinic; J. Feld, MD, Rheumatology Unit, Carmel Medical Center; D. Zisman, MD, Rheumatology Unit, Carmel Medical Center; D.D. Gladman, MD, FRCPC, Department of Medicine, University of Toronto, and Centre for Prognosis Studies in the Rheumatic Diseases, Toronto Western Hospital.

PMID: 29419462
PMCID: PMC5845845
DOI: 10.3899/jrheum.170379

Abstract

Objective: We aimed to estimate the proportion of underdiagnosis and undertreatment of cardiovascular risk factors (CVRF) in an international multicenter cohort of patients with psoriasis and psoriatic arthritis (PsA).

Methods: A cross-sectional analysis was conducted of patients with psoriatic disease from the International Psoriasis and Arthritis Research Team cohort. The presence of modifiable CVRF [diabetes, hypertension (HTN), dyslipidemia, smoking, elevated body mass index, and central obesity] and the use of appropriate therapies for HTN and dyslipidemia were determined. The 10-year CV risk was calculated according to the Framingham Risk Score. Physician adherence with guidelines for the treatment of dyslipidemia and HTN was assessed. Regression analysis was used to assess predictors of undertreatment of HTN and dyslipidemia.

Results: A total of 2254 patients (58.9% PsA, 41.1% psoriasis) from 8 centers in Canada, the United States, and Israel were included. Their mean age was 52 ± 13.8 years and 53% were men. Of the patients, 87.6% had at least 1 modifiable CVRF, 45.1% had HTN, 49.4% dyslipidemia, 13.3% diabetes, 75.3% were overweight or obese, 54.3% central obesity, and 17.3% were current smokers. We found 59.2% of patients with HTN and 65.6% of patients with dyslipidemia were undertreated. Undertreatment was associated with younger age (≤ 50 yrs), having psoriasis, and male sex.

Conclusion: In real-world settings, a large proportion of patients with psoriasis and PsA were underdiagnosed and undertreated for HTN and dyslipidemia. Strategies to improve the management of CVRF in psoriatic patients are warranted.

Keywords: CARDIOVASCULAR DISEASES; EPIDEMIOLOGY; PSORIATIC ARTHRITIS.

PubMed Disclaimer

Figures

**Figure 1. The prevalence of CV Risk Factors by site (%)**

**Figure 2. Factors associated with Undertreatement of Hypertension Odds Ratio (95% Confidence Intervals)**

**Figure 3. Factors associated with Undertreatement of Deyslipidemia Odds Ratio (95% Confidence Intervals)**

See this image and copyright information in PMC

Comment in

Optimization of CVD prevention in psoriatic arthritis.
Semb AG, Rollefstad S. Semb AG, et al. Nat Rev Rheumatol. 2018 Jun;14(6):323-324. doi: 10.1038/s41584-018-0002-z. Nat Rev Rheumatol. 2018. PMID: 29686327 No abstract available.

Cited by

Psoriatic arthritis and the association with cardiometabolic disease: a narrative review.
Karmacharya P, Ogdie A, Eder L. Karmacharya P, et al. Ther Adv Musculoskelet Dis. 2021 Mar 2;13:1759720X21998279. doi: 10.1177/1759720X21998279. eCollection 2021. Ther Adv Musculoskelet Dis. 2021. PMID: 33737966 Free PMC article. Review.
Clinicians' perspectives of shared care of psoriatic arthritis and psoriasis between rheumatology and dermatology: an interview study.
Sumpton D, Hannan E, Kelly A, Tunnicliffe D, Ming A, Hassett G, Craig JC, Tong A. Sumpton D, et al. Clin Rheumatol. 2021 Apr;40(4):1369-1380. doi: 10.1007/s10067-020-05391-y. Epub 2020 Sep 15. Clin Rheumatol. 2021. PMID: 32935247
A Care Coordination Model to Prevent Cardiovascular Events in Patients with Psoriatic Disease: A Multicenter Pilot Study.
Song WB, Garshick MS, Barbieri JS, Shin DB, Báez S, Papadopoulos M, Neopaney A, Fitzsimmons R, Kalb RE, Mease PJ, Craig ET, Koplin J, Takeshita J, Chiesa Fuxench ZC, Armstrong AW, Mehta NN, Beidas RS, Ogdie AR, Gelfand JM. Song WB, et al. J Invest Dermatol. 2024 Jun;144(6):1405-1409.e1. doi: 10.1016/j.jid.2023.12.008. Epub 2024 Jan 4. J Invest Dermatol. 2024. PMID: 38184142 Free PMC article. No abstract available.
Cardiovascular disease risk in patients with inflammatory arthritis nowadays still substantially elevated.
Raadsen R, Hansildaar R, Pouw LC, Hooijberg F, Boekel L, Wolbink GJ, van Kuijk AWR, Nurmohamed MT. Raadsen R, et al. RMD Open. 2023 Dec 1;9(4):e003485. doi: 10.1136/rmdopen-2023-003485. RMD Open. 2023. PMID: 38053460 Free PMC article.
Cardiovascular Risk Scores in Axial Spondyloarthritis Versus the General Population: A Cross-sectional Study.
Liew JW, Reveille JD, Castillo M, Sawhney H, Naovarat BS, Heckbert SR, Gensler LS. Liew JW, et al. J Rheumatol. 2021 Mar;48(3):361-366. doi: 10.3899/jrheum.200188. Epub 2020 Jul 1. J Rheumatol. 2021. PMID: 32611668 Free PMC article.

See all "Cited by" articles

References

1. Armstrong EJ, Harskamp CT, Armstrong AW. Psoriasis and major adverse cardiovascular events: a systematic review and meta-analysis of observational studies. J Am Heart Assoc. 2013;2:e000062. - PMC - PubMed
1. Polachek A, Touma Z, Anderson M, Eder L. Risk of Cardiovascular Morbidity in Patients With Psoriatic Arthritis: A Meta-Analysis of Observational Studies. Arthritis Care Res (Hoboken) 2017;69:67–74. - PubMed
1. Maradit-Kremers H, Icen M, Ernste FC, Dierkhising RA, McEvoy MT. Disease severity and therapy as predictors of cardiovascular risk in psoriasis: a population-based cohort study. J Eur Acad Dermatol Venereol. 2012;26:336–43. - PMC - PubMed
1. Gelfand JM, Neimann AL, Shin DB, Wang X, Margolis DJ, Troxel AB. Risk of myocardial infarction in patients with psoriasis. JAMA. 2006;296:1735–41. - PubMed
1. Miller IMea. Meta-analysis of psoriasis, cardiovascular disease, and associated risk factors -supplement - PubMed

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Grants and funding

LinkOut - more resources

Full Text Sources
Other Literature Sources
- scite Smart Citations
Medical
- MedlinePlus Health Information
Research Materials
- NCI CPTC Antibody Characterization Program
Miscellaneous
- NCI CPTAC Assay Portal

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Gaps in Diagnosis and Treatment of Cardiovascular Risk Factors in Patients with Psoriatic Disease: An International Multicenter Study

Affiliations

Gaps in Diagnosis and Treatment of Cardiovascular Risk Factors in Patients with Psoriatic Disease: An International Multicenter Study

Authors

Affiliations

Abstract

Figures

Comment in

Similar articles

Cited by

References

Publication types

MeSH terms

Grants and funding

LinkOut - more resources

Full Text Sources

Other Literature Sources

Medical

Research Materials

Miscellaneous

Abstract

Figures

Comment in

Similar articles

Cited by

References

Publication types

MeSH terms

Related information

Grants and funding

LinkOut - more resources

Full Text Sources

Other Literature Sources

Medical

Research Materials

Miscellaneous